hMLH1, hMSH2 and cyclooxygenase-2 (Cox-2) in sporadic colorectal polyps

被引:0
|
作者
Balbinotti, Raul Angelo [1 ]
Ribeiro, Ulysses, Jr. [2 ]
Saka, Paulo [2 ]
Safatle-Ribeiro, Adriana Vaz [2 ]
Balbinotti, Silvana Sartori [1 ]
Scapulatempo, Cristovam [2 ]
Alves, Venancio Avancini Ferreira [3 ]
Corbett, Carlos Eduardo Pereira [2 ,3 ]
机构
[1] Univ Caxias do Sul, Sch Med, Dept Gastroenterol, Caxias Do Sul, RS, Brazil
[2] Univ Sao Paulo, Sch Med, Dept Gastroenterol, BR-05508 Sao Paulo, Brazil
[3] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05508 Sao Paulo, Brazil
关键词
hMLH1; hMSH2; Cox-2; immunohistochemistry; adenomas; polyps; colorectal cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Colorectal adenomatous polyps are known as premalignant lesions. Mutations in the mismatch repair (MMR) enzymes hMLH1, hMSH2 and hMSH6 are recognized causes of hereditary non-polyposis colorectal cancer and act by inducing a mutator phenotype characterized by microsatellite instability (MSI). MSI is also detected in sporadic colorectal cancers. Cox-2 is an inducible enzyme that regulates prostaglandin synthesis and it is overexpressed at sites of inflammation, in colorectal adenomatous polyps and cancer. The aim of this study was to evaluate the immunoexpression of hMLH1, hMSH2 and Cox-2 in polyps resected through colonoscopy, and to examine their association with clinicopathological characteristics (age, gender, location, size, histology and grade of dysplasia). Patients and Methods: One hundred and sixty-seven colonic polyps, 6 normal colonic mucosa samples, and 23 samples of colorectal adenocarcinoma were used in this study. All patients had no family history of colorectal cancer. The samples were prospectively collected and immunostained for hMLH1 hMSH2 and Cox-2 using the ABC-immunohistochemistry technique with amplification by biotinylated tyramide. The mean age was 60.2 +/- 13.8 years (range 21-90 years) and 77 (55.8%) were men. Results: Tubular adenomas were present in 81.4%, tubulous-villous in 15.9%, serrated in 1.8%, and villous in 0.9%. The majority of the adenomas were located in the rectosigmoid region (63.5%), followed by ascendant in 14.2%, cecum in 7.5%, descendent in 8.2% and transverse in 6.7%. Low-grade dysplasia was detected in 59.6% of the adenomas. Loss of hMLH1 and hMLH2 immunoexpression was observed in 20% and 15.5% of the adenomas, respectively. Cox-2 expression was found in 9% of the adenomas, and in 40% of the adenocarcinomas. Moreover, Cox-2 immunoexpression was associated with the multiplicity of adenomas in the same patient (p=0.001). There was no association between marker immunoexpression and gender, age, location, size, histology or grade of dysplasia. Conclusion: Loss of hMLH1 and hMLH2 immunoexpression in adenomas is relatively frequent in patients without colorectal cancer family history. Cox-2 is overexpressed in colorectal adenomatous polyps and adenocarcinomas, and its positivity in adenomas may indicate a higher risk for multiple lesions.
引用
收藏
页码:4465 / 4471
页数:7
相关论文
共 50 条
  • [41] Expression of cyclooxygenase-2 (COX-2) in pituitary tumours
    Sokolowski, Grzegorz
    Baldys-Waligorska, Agata
    Trofimiuk, Malgorzata
    Adamek, Dariusz
    Hubalewska-Dydejczyk, Alicja
    Golkowski, Filip
    MEDICAL SCIENCE MONITOR, 2012, 18 (04): : CR252 - CR259
  • [42] Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium
    Vageli, Dimitra P.
    Giannopoulos, Stavros
    Doukas, Sotirios G.
    Kalaitzis, Christos
    Giannakopoulos, Stilianos
    Giatromanolaki, Alexandra
    Koukoulis, George K.
    Touloupidis, Stavros
    ONCOLOGY LETTERS, 2013, 5 (01) : 283 - 294
  • [43] Matrix Metalloproteinases (MMP-2 and MMP-9) and Cyclooxygenase-2 (COX-2) Expressions in Vocal Fold Polyps
    Karahan, Nermin
    Baspinar, Sirin
    Yariktas, Murat
    Kapucuoglu, Nilgun
    JOURNAL OF VOICE, 2009, 23 (01) : 29 - 33
  • [44] Cyclooxygenase-2 (COX-2) in carcinogenesis and selective cox-2 inhibitors for chemoprevention in gastrointestinal cancers
    Fujimura T.
    Ohta T.
    Oyama K.
    Miyashita T.
    Miwa K.
    Journal of Gastrointestinal Cancer, 2007, 38 (2-4) : 78 - 82
  • [45] Reduced expression of hMLH1 and hMSH2 gene products in high-grade hepatocellular carcinoma
    Wani, Y
    Notohara, K
    Tsukayama, C
    Okada, S
    ACTA MEDICA OKAYAMA, 2001, 55 (02) : 65 - 71
  • [46] Immunohistochemical analysis of expression and allelotype of mismatch repair genes (hMLH1 and hMSH2) in bladder cancer
    H Sh Kassem
    J M Varley
    S M Hamam
    G P Margison
    British Journal of Cancer, 2001, 84 : 321 - 328
  • [47] Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma
    Uehara, H
    Miyamoto, M
    Kato, K
    Cho, Y
    Kurokawa, T
    Murakami, S
    Fukunaga, A
    Ebihara, Y
    Kaneko, H
    Hashimoto, H
    Murakami, Y
    Shichinohe, T
    Kawarada, Y
    Itoh, T
    Okushiba, S
    Kondo, S
    Katoh, H
    JOURNAL OF SURGICAL ONCOLOGY, 2005, 92 (02) : 109 - 115
  • [48] Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas
    Rossmeisl, J. H., Jr.
    Robertson, J. L.
    Zimmerman, K. L.
    Higgins, M. A.
    Geiger, D. A.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (03) : 173 - 180
  • [49] Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma
    Trojan, A
    Tinguely, M
    Vallet, S
    Seifert, B
    Jenni, B
    Zippelius, A
    Witzens-Harig, M
    Mechtersheimer, G
    Ho, AD
    Goldschmidt, H
    Jäger, D
    Boccadoro, M
    Ladetto, M
    SWISS MEDICAL WEEKLY, 2006, 136 (25-26) : 400 - 403
  • [50] Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    VETERINARY SCIENCES, 2024, 11 (02)